Oboya signs a cooperation agreement with Gaia regarding biomaterials

Dela

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry.

Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide.

The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are biodegradable, compostable and reduce up to 80% lower carbon dioxide emissions during combustion compared to conventional materials such as plastic and paper. The new environmentally friendly product concept includes everything from pots, packaging and trays to labels and will be launched in beginning of 2019. Oboya is aiming to grow in the environmentally friendly cultivation products segment, selling to several of Oboya's home markets in Europe and China.

"The cooperation agreement with Gaia allows us to be at the frontline of offering environmentally friendly products to our customers as well as meeting the demands that are made to achieve a sustainable production chain. It is important for us that our business affects people and the environment in as many positive ways as possible. We are taking an important step in the right direction and working for a sustainable cultivation industry ", said Robert Wu, CEO of Oboya Horticulture Industries AB.

Erik Penser Bank is Oboyas Certified Adviser at Nasdaq First North. 

For any inquiry regarding this press release, kindly contact:

 

Robert Wu, CEO of Oboya Horticulture Industries AB (publ)

 

Phone: + 86 159 6983 5999

E-mail: robert.wu@oboya.cc

Homepage: www.oboya.se


About Oboya Horticulture Industries AB

Oboya Horticulture aims to become a world-leading total supplier of consumables and logistics products for the cultivation industry as well as consumer products for home cultivation and indoor environments. Production takes place in factories in China, Poland, Denmark, Vietnam and Kenya. More information about the company is available at www.oboya.se.




This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oboya Horticulture Industries AB via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Conferences in March and April22.3.2019 08:00:00 CETPressmeddelande

Press Release 22 March 2019 Immunicum AB (publ) Announces Upcoming Conferences in March and April Immunicum AB (publ; IMMU.ST) announced today that members of the management team will attend and present at upcoming conferences in March and April. BIO-Europe Spring Date: March 25-27, 2019 Venue: Messe Wien Exhibition and Congress Center, Vienna, Austria Participant: Sijme Zeilemaker China Focus @ Europe Vienna Date: March 27, 2019 Panel Time/Session: 16.10 - 17.00, Panel 4: Partnering Opportunities with Chinese Pharma Venue: Hilton Vienna Danube Waterfront, Vienna, Austria Participant: Carlos de Sousa Swedish American Life Science Summit 2019 Date: April 9-10, 2019 Presentation Date: Wednesday, April 10, 2019 Venue: House of Sweden, 2900 K St. NW, Washington D.C. 20008 Participant: Carlos de Sousa For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 8 732 8400 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir

Immunicum AB (publ) meddelar kommande konferenser i mars och april22.3.2019 08:00:00 CETPressmeddelande

Pressmeddelande 22 mars 2019 Immunicum AB (publ) meddelar kommande konferenser i mars och april Immunicum AB (publ; IMMU.ST) meddelar idag att medlemmar av ledningsgruppen kommer att delta och presentera vid kommande konferenser i mars och april. BIO-Europe Spring Datum: 25-27 mars 2019 Plats: Messe Wien Exhibition and Congress Center, Wien, Österrike Deltagare: Sijme Zeilemaker China Focus @ Europe Vienna Datum: 27 mars 2019 Paneltid/Sessionstid: 16.10 - 17.00, Panel 4: Partnering Opportunities with Chinese Pharma Plats: Hilton Vienna Danube Waterfront, Wien, Österrike Deltagare: Carlos de Sousa Swedish American Life Science Summit 2019 Datum: 9-10 april 2019 Presentationsdatum: Onsdagen 10 april 2019 Plats: House of Sweden, 2900 K St. NW, Washington D.C. 20008 Deltagare: Carlos de Sousa För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 8 732 8400 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@i

Karolinska Development's portfolio company Promimic announces partnership with Onkos Surgical15.3.2019 08:45:00 CETPressmeddelande

STOCKHOLM, March 15, 2019. Karolinska Development's portfolio company Promimic announces a new partnership with the U.S company Onkos Surgical® to commercialize Promimic's proprietary Hydroxyapatite (HA) Surface Technologies in Limb Salvage Surgery. Promimic develops and markets products within nano-materials for innovative surface treatments and has developed the HA nano Surface that is clinically proven to speed up and improve the anchoring of implants in bone. The innovative technology is already licensed to several dental implant companies. The partnership with Onkos Surgical®, a U.S company addressing the clinical challenges associated with tumor surgery, represents an important step into the orthopaedic space. The partnership will focus on combining Promimic's HA nano Surface Technology with Onkos Surgical®'s ELEOS Limb Salvage Portfolio. Implant failure due to aseptic loosening remains one of the key challenges associated with limb salvage surgery. With HA nano Surface, Onkos Su

Karolinska Development's portfolio company Promimic announces partnership with Onkos Surgical15.3.2019 08:45:00 CETPressmeddelande

STOCKHOLM, March 15, 2019. Karolinska Development's portfolio company Promimic announces a new partnership with the U.S company Onkos Surgical® to commercialize Promimic's proprietary Hydroxyapatite (HA) Surface Technologies in Limb Salvage Surgery. Promimic develops and markets products within nano-materials for innovative surface treatments and has developed the HA nano Surface that is clinically proven to speed up and improve the anchoring of implants in bone. The innovative technology is already licensed to several dental implant companies. The partnership with Onkos Surgical®, a U.S company addressing the clinical challenges associated with tumor surgery, represents an important step into the orthopaedic space. The partnership will focus on combining Promimic's HA nano Surface Technology with Onkos Surgical®'s ELEOS Limb Salvage Portfolio. Implant failure due to aseptic loosening remains one of the key challenges associated with limb salvage surgery. With HA nano Surface, Onkos Su

Karolinska Development's portfolio company Forendo Pharma announces positive results from a Phase Ia study of FOR 62197.3.2019 09:00:00 CETPressmeddelande

STOCKHOLM, March 7, 2019. Karolinska Development's portfolio company Forendo Pharma today announces positive results from a Phase Ia study with the drug candidate FOR 6219 for the treatment of endometriosis. The results found FOR 6219 to be safe and well tolerated, with good pharmacokinetics at the doses tested. The randomized, double blind, placebo controlled Phase Ia study investigated the safety, tolerability, food effect and pharmacokinetics of single and multiple ascending oral doses of FOR 6219 in 36 healthy postmenopausal women. In the study, single doses of FOR 6219 from 2 mg up to 175 mg and multiple doses up to 150 mg twice daily for ten days were found to be safe and well tolerated. The pharmacokinetic results showed a dose proportionate exposure and no significant food effect. The safety and pharmacokinetic profile of FOR 6219 supports the initiation of a Phase Ib clinical trial in healthy premenopausal women with the aim to demonstrate Proof of Mechanism. The selective abi

Karolinska Development's portfolio company Forendo Pharma announces positive results from a Phase Ia study of FOR 62197.3.2019 09:00:00 CETPressmeddelande

STOCKHOLM, March 7, 2019. Karolinska Development's portfolio company Forendo Pharma today announces positive results from a Phase Ia study with the drug candidate FOR 6219 for the treatment of endometriosis. The results found FOR 6219 to be safe and well tolerated, with good pharmacokinetics at the doses tested. The randomized, double blind, placebo controlled Phase Ia study investigated the safety, tolerability, food effect and pharmacokinetics of single and multiple ascending oral doses of FOR 6219 in 36 healthy postmenopausal women. In the study, single doses of FOR 6219 from 2 mg up to 175 mg and multiple doses up to 150 mg twice daily for ten days were found to be safe and well tolerated. The pharmacokinetic results showed a dose proportionate exposure and no significant food effect. The safety and pharmacokinetic profile of FOR 6219 supports the initiation of a Phase Ib clinical trial in healthy premenopausal women with the aim to demonstrate Proof of Mechanism. The selective abi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum